# Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen

Study · id `cardio:ct-nct04013581` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04013581](<https://clinicaltrials.gov/study/NCT04013581>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04013581

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

## Technical summary

Registry record NCT04013581. Randomized; no masking; primary purpose treatment. Start 2019-08-05 (actual); primary completion 2020-05-13 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 121 participants (enrolled count; ClinicalTrials.gov record NCT04013581, source copy `cardio:ctgov-nct04013581-2021-05-04`, retrieved 2026-10-26)
- Started: 2019-08-05 (actual) (ClinicalTrials.gov record NCT04013581, source copy `cardio:ctgov-nct04013581-2021-05-04`, retrieved 2026-10-26)
- Primary completion: 2020-05-13 (actual) (ClinicalTrials.gov record NCT04013581, source copy `cardio:ctgov-nct04013581-2021-05-04`, retrieved 2026-10-26)
- Completion: 2020-05-28 (actual) (ClinicalTrials.gov record NCT04013581, source copy `cardio:ctgov-nct04013581-2021-05-04`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04013581, source copy `cardio:ctgov-nct04013581-2021-05-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04013581-2021-05-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): TZD group
- Intervention (Drug): SGLT-2 group
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: 44ad9fe628e2d3031388305ba4f83029fec4cc726ec697541690a675e8638387
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
